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Long-term follow-up of a trial comparing 
post-remission treatment with autologous or 
allogeneic bone marrow transplantation or intensive
chemotherapy in younger acute myeloid leukemia
patients 
Even though the optimal post-remission therapy for
younger acute myeloid leukemia (AML) patients has
remained controversial1 only a few prospective trials
have been comparing intensive chemotherapy to autolo-
gous (auto-) or allogeneic (allo-) bone marrow transplan-
tation (BMT). In addition, most of these studies have
been published with a relatively short follow-up.2
Therefore, we herein report a very long-term follow-up
evaluation of AML patients previously enrolled in the
pivotal EORTC/GIMEMA AML-8A trial.3
From November 1986 to April 1993, 990 patients were
registered in the EORTC/GIMEMA AML-8A trial which
prospectively compared the impact of three post-remis-
sion treatments on disease-free (DFS) and overall (OS)
survival in younger (10-45 years of age) AML patients
who reached a complete remission (CR) after induction
chemotherapy (Online Supplementary Figure 1). Main
inclusion criteria included previously untreated AML
according to the French-American-British (FAB) classifica-
tion system and 10 to 59 years of age at diagnosis 
(NB: some centers accepted to enter patients aged 46-59
years of age). Main exclusion criteria included AML
occurring after a myeloproliferative disorder, and a prior
history of myelodysplastic syndrome for more than six
months. Thirty-six of the 990 patients were deemed inel-
igible because of inadequate diagnosis or because they
met exclusion criteria. Further 13 patients could not be
evaluated because of missing data. Thus, data from 941
patients were evaluated. The results were first reported
in 1995 with a median follow-up of 3.3 years after regis-
tration.3 All patients received a remission-induction con-
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Table 1. Patient characteristics, treatment applicability and outcomes according to the three treatments planned at the evaluation of ICT1.
                                                                   Allo-BMT (n=168)             Auto-BMT (n=128)                      ICT2 (n=126)                             P
Age at registration                                                                                                                                                                                                                               
Median (range)                                                             32 (13-45)                              32.5 (15-59)                                     32 (15-59)                                   0.80*
11-25, n (%)                                                                  42 (25)                                     42 (33)                                            45 (36)                                           
26-45, n (%)                                                                 126 (75)                                    77 (60)                                            72 (57)                                           
46-59, n (%)                                                                        0                                             9 (7)                                                9 (7)                                             
White-cell count at registration x109/L                                                                                                                                                                                          
Median (range)                                                         14.8 (0.4-294)                          14.7 (0.5-288)                                 13.8 (0.2-376)                                0.98*
< 5, n (%)                                                                    37 (22)                                     39 (31)                                            33 (26)                                           
5-49, n (%)                                                                   98 (58)                                     54 (42)                                            59 (47)                                           
≥ 50, n (%)                                                                  33 (20)                                     35 (27)                                            34 (27)                                           
Cytogenetic risk, n (%)*                                                 n=73                                         n=59                                                n=56                                       0.45**
Good                                                                              18 (25)                                     11 (19)                                             7 (13)                                            
Intermediate                                                                25 (34)                                     24 (41)                                            17 (30)                                           
Poor                                                                                14 (19)                                     12 (20)                                            11 (20)                                           
Inconclusive                                                                 16 (22)                                     12 (20)                                            21 (38)                                           
# of cycles needed to reach a CR, n (%)                                                                                                                                                                                  0.052*
1                                                                                    132 (79)                                   111 (87)                                          111 (88)                                          
2                                                                                      36 (21)                                     17 (13)                                            15 (12)                                           
Treatment given in CR1, n (%)                                                                                                                                                                                                         
Allo-BMT                                                                     144 (86)                                      2 (2)                                                 1(1)                                             
Auto-BMT                                                                           0                                           95 (74)                                              5 (4)                                             
ICT2                                                                                 1 (1)                                         5 (4)                                             104 (83)                                          
Other                                                                                  0                                             3 (2)                                                1 (1)                                             
None                                                                             23 (14)                                     23 (18)                                            15 (12)                                           
Median length of time between CR                                15                                               14                                                      10                                        <0.001*
achievement and last treatment step (weeks)              
Disease free-survival status, n (%)                                                                                                                                                                                                 
CR1                                                                                      87 (52)                                     52 (41)                                            39 (31)                                           
Relapse                                                                              47 (28)                                     60 (47)                                            76 (60)                                           
Death without relapse                                                   34 (20)                                     16 (13)                                             11 (9)                                            
Patients given a salvage auto-BMT, n (%)                       0                                             2 (2)                                              13 (10)                                           
Patients given a salvage allo-BMT, n (%)                     2 (1)                                         1 (1)                                                2 (2)                                             
*Kruskal-Wallis test ; **: Yates’ c2 test. ICT: intensive consolidation chemotherapy; allo-BMT: autologous bone marrow transplantation; auto-BMT:allogeneic bone marrow
transplantation; CR:complete remission; CR1: first complete remission. ICT: intensive consolidation chemotherapy.
sisting of one or two (in case of partial response after the
first course) courses of chemotherapy combining cytara-
bine (200 mg/m2 given as a continuous intravenous (iv)
infusion on days 1 through day 7) and daunorubicine (45
mg/m2 given iv on days 1, 2 and 3). CR was reached by
623 patients (66%) after one or two courses of induction
and 576 of these patients received the first course of
intensive consolidation chemotherapy (ICT1) combining
intermediate-dose cytarabine (1000 mg/m2 during the
first year of the study and then 500 mg/m2, given iv in
two hours every 12 hours on day 1 through day 6), and
amsacrine (given iv at a dose of 120 mg/m2 on days 5, 6,
and 7). After ICT1, patients alive in first complete remis-
sion (CR1) who had an human leukocyte antigen 
(HLA)-compatible donor, and considered suitable to
receive an allo-BMT, were included in the allo-BMT arm.
Patients alive in CR1 without a HLA-compatible donor,
and considered eligible to receive an auto-BMT, were
randomized between auto-BMT and a second course of
intensive consolidation chemotherapy (ICT2). The distri-
butions of OS, DFS from CR and OS from CR1 were esti-
mated using the Kaplan-Meier method and  the treat-
ment groups were compared using the log-rank test. The
Cox model was used to estimate the treatment hazard
ratios along with the 95% confidence interval (CI). The
relapse incidence as well as the incidence of death in CR
were calculated using cumulative incidence functions and
the groups were compared using the Gray test. 
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Figure 1. Outcomes based on intent-to-treatment analyses. (A) OS from inclusion in the whole population. (B) DFS from CR according to treatment group. (C)
Cumulative incidence of relapse from CR according to treatment group. (D) Cumulative incidence death in CR from CR according to treatment group. (E) OS from
CR according to treatment group. (F) DFS in patients alive in first CR 5 years after the achievement of CR, according to treatment group. OS: overall survival;
DFS: disease-free survival; CR: complete remission. 
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In the current report, the median follow-up from inclu-
sion was 11.1 years (95% CI 10-13 years; range 0-28
years). For the whole population (n=941), the 5-, 10- and
15-year OS rates from inclusion were 35%, 32% and
31%, respectively (Figure 1A). A total of 623 patients
(66%) achieved a CR after one (n=508) or two (n=116)
course(s) of induction chemotherapy. Out of 576 patients
who completed ICT1, 168 were allocated to the allo-
BMT arm, while 254 patients were randomized to auto-
BMT (n=128) or ICT2 (n=126). The outcomes of these
three treatment groups (n=422) are reported below.
As observed in the initial report,3 DFS from CR was
longer after allo-BMT than auto-BMT and was also
longer after auto-BMT than after ICT2 (Figure 1B;
P=0.015). Specifically, the five-year DFS from CR was
55% in the allo-BMT group, 46% in the auto-BMT group
and 33% in the ICT2 group. At 10-year from inclusion,
DFS from CR were 52%, 44% and 30% in the allo-BMT,
auto-BMT and ICT2 patients, respectively. Restricting
the analyses to patients < 46 years of age at registration
(before the start of the induction treatment), the 10-year
DFS from CR was 52%, 47% and 30% in the allo-BMT,
auto-BMT and ICT2 patients, respectively (P=0.016)
(Online Supplementary Figure 2A). Interestingly, subgroup
analyses suggested that the advantage of allo-BMT was
mainly observed in patients lacking good-risk cytogenetic
features (Online Supplementary Figure 2B) and not in those
with good-risk features (Online Supplementary Figure 2C).
In the 422 patient group, the 10-year relapse incidence
from CR was lower in the allo-BMT group (28%) than in
the auto-BMT (47%) and in the ICT2 group (62%)
(Figure 1C; P=0.001), while the 10-year incidence of
death in CR was higher in the allo-BMT (20%) than in
the auto-BMT (10%) and in the ICT2 group (8%) (Figure
1D; P=0.019). In contrast to what was observed for DFS
from CR, OS from CR was not significantly impacted by
the treatment group (Figure 1E, P=0.61). Specifically, the
10-year OS from CR rate was 55% in the allo-BMT
group, 49% in the auto-BMT group, and 46% in the
ICT2 group. This might have been due to higher rates of
salvage auto- or allo-BMT in the ICT2 group (12%) than
in the auto-BMT (3%) and allo-BMT (1%) group (Table
1), given that both strategies proved to be effective in
selected patients with relapsed AML.4,5 As depicted in
Figure 1F and the Online Supplementary Figure 2D, rela-
tively few events occurred beyond five years after the
study inclusion. Specifically, among the patients alive,
still in first CR five years after the achievement of CR, the
10-year DFS rate and 10-year relapse incidence from CR1
were 94% and 3% in the allo-BMT group (n=90), 96%
and 5% in the auto-BMT patients (n=56) and 90% and
7% in the ICT2 patients (n=36), respectively. Several
deaths occurring approximately 20 years after the
achievement of CR were not due to AML. 
The comparison of the results of the two randomized
groups showed that the patients randomized to the auto-
BMT arm had a longer DFS from randomization than the
patients in the ICT2 group (HR=0.78; 95% CI: 0.57-1.07,
P=0.12) due to a lower incidence of relapse (HR=0.71;
95% CI: 0.51-1.00, P=0.050). In contrast, OS from ran-
domization was comparable in the auto-BMT and ICT2
groups (HR=0.97; 95% CI: 0.69-1.36, P=0.9). This also
might be explained by the relatively high incidence of sal-
vage auto-BMT in the ICT2 group (10% versus 2% in the
auto-BMT patients) (Table 1).
Previous studies have noted that non relapse fatalities
due in part to complications of chronic graft-versus-host
disease (GvHD) may occur well beyond five years post
transplantation,6 while late relapses have been reported
especially in patients not offered an allogeneic transplan-
tation.7 These observations prompted us to perform a
long-term follow-up of the pivotal EORTC/GIMEMA
AML-8A trial comparing three post-remission strategies. 
A first novel finding was that our initial observations
hold true after a long-term follow up, with a benefit in
terms of DFS from CR in the allo-BMT patients in com-
parison to the auto-BMT and further to the ICT2
patients. These results are in concordance with those
observed by Vallenga et al. who reported better five-year
relapse free survival with autologous peripheral blood
stem cell (PBSC) transplantation than with intensive
chemotherapy in AML patients, in first CR after 2 cycles
of intensive chemotherapy, who did not have a HLA-
identical sibling donor.8
A second important result from the current analysis is
that among AML patients in CR five years after the study
inclusion, the probability to remain alive and disease free
five years later was >90%, and was quite similar in the
three post-remission treatment groups. The long-term
analyses of the health related quality of life (HRQOL) of
the patients is planned in a further study (the SPARTA
platform). 
It should be noted that, in the AML arena, many
advances have been made in each group since the
EORTC/GIMEMA AML-8A study was designed. These
include, for example, GvHD prophylaxis (they had short-
er OS than those receiving cyclosporine A plus
methotrexate for GvHD prophylaxis), better conditioning
regimens for each auto-BMT and allo-BMT9, the demon-
stration of the importance of high-dose cytarabine-based
consolidation chemotherapy in patients with core-bind-
ing factor leukemia and important advances in the sup-
portive care.10 Also the dose of the intercalating agent
used in the remission induction chemotherapy (3 x 45
mg/m2 of daunorubicin) was suboptimal according to
more recent studies. Finally, autologous transplantation is
nowadays performed with PBSC instead of with BM as a
stem cell source although one large registry and one
phase III study did not show better DFS with auto-
PBSCT than with auto-BMT.11,12
In summary, this long-term follow-up of the
EORTC/GIMEMA AML-8A study confirms a longer DFS
with allo-BMT or auto-BMT when compared to ICT2 in
younger AML patients in CR1. Further, this long-term
follow-up study revealed that the vast majority of
patients alive in CR1 at  five years remain disease-free
survivors five years later. Although indications of allo-
geneic hematopoietic stem cell transplantation are nowa-
days largely driven by the cytogenetic/molecular AML
profile10,13 and the presence or absence of minimal resid-
ual disease at transplantation,14 long-term results of the
AML-8A study demonstrate that auto-BMT remained
superior to ICT2 in younger AML patients not candidate
for an allo-HSCT. These results suggest that new
prospective trials comparing autologous hematopoietic
stem cell transplantation to additional intensive
chemotherapy should be carried out. These studies could
include patients with favorable European Leukemia Net
classification risk with minimal residual disease (MRD)
negative levels.15
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